Femme Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective is to evaluate the effect of denosumab 60 mg q 6 months on total hip bone mineral density (BMD) at 12 months in postmenopausal women with low BMD previously treated with alendronate 70 mg QW or equivalent compared to that in subjects continuing on alendronate therapy.
Critère d'inclusion
- Postmenopausal osteoporosis /osteopenia